|
Gene: TFRC |
Gene summary for TFRC |
Gene summary. |
Gene information | Species | Human | Gene symbol | TFRC | Gene ID | 7037 |
Gene name | transferrin receptor | |
Gene Alias | CD71 | |
Cytomap | 3q29 | |
Gene Type | protein-coding | GO ID | GO:0000018 | UniProtAcc | P02786 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7037 | TFRC | CA_HPV_1 | Human | Cervix | CC | 2.97e-03 | 2.03e-01 | 0.0264 |
7037 | TFRC | CA_HPV_2 | Human | Cervix | CC | 3.34e-03 | 3.43e-01 | 0.0391 |
7037 | TFRC | CCI_2 | Human | Cervix | CC | 1.20e-15 | 1.68e+00 | 0.5249 |
7037 | TFRC | CCI_3 | Human | Cervix | CC | 1.78e-12 | 1.01e+00 | 0.516 |
7037 | TFRC | HTA11_3410_2000001011 | Human | Colorectum | AD | 7.23e-04 | -3.30e-01 | 0.0155 |
7037 | TFRC | HTA11_866_3004761011 | Human | Colorectum | AD | 4.22e-02 | -3.02e-01 | 0.096 |
7037 | TFRC | HTA11_99999970781_79442 | Human | Colorectum | MSS | 5.25e-08 | 6.93e-01 | 0.294 |
7037 | TFRC | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 4.91e-07 | 1.28e+00 | 0.3487 |
7037 | TFRC | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.16e-08 | 8.95e-01 | 0.281 |
7037 | TFRC | F007 | Human | Colorectum | FAP | 2.54e-03 | -3.41e-01 | 0.1176 |
7037 | TFRC | A001-C-207 | Human | Colorectum | FAP | 2.23e-03 | -2.21e-01 | 0.1278 |
7037 | TFRC | A015-C-203 | Human | Colorectum | FAP | 2.88e-15 | -2.38e-01 | -0.1294 |
7037 | TFRC | A015-C-204 | Human | Colorectum | FAP | 3.12e-06 | -2.56e-01 | -0.0228 |
7037 | TFRC | A014-C-040 | Human | Colorectum | FAP | 8.46e-03 | -3.76e-01 | -0.1184 |
7037 | TFRC | A002-C-201 | Human | Colorectum | FAP | 4.14e-11 | -1.88e-01 | 0.0324 |
7037 | TFRC | A002-C-203 | Human | Colorectum | FAP | 1.37e-02 | -1.92e-01 | 0.2786 |
7037 | TFRC | A001-C-119 | Human | Colorectum | FAP | 5.12e-11 | -3.69e-01 | -0.1557 |
7037 | TFRC | A001-C-108 | Human | Colorectum | FAP | 3.67e-10 | -3.13e-01 | -0.0272 |
7037 | TFRC | A002-C-205 | Human | Colorectum | FAP | 7.54e-18 | -3.43e-01 | -0.1236 |
7037 | TFRC | A015-C-005 | Human | Colorectum | FAP | 3.44e-03 | -2.13e-01 | -0.0336 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000941018 | Oral cavity | OSCC | response to xenobiotic stimulus | 222/7305 | 462/18723 | 4.00e-05 | 3.48e-04 | 222 |
GO:000689810 | Oral cavity | OSCC | receptor-mediated endocytosis | 125/7305 | 244/18723 | 6.56e-05 | 5.32e-04 | 125 |
GO:00510925 | Oral cavity | OSCC | positive regulation of NF-kappaB transcription factor activity | 82/7305 | 152/18723 | 1.28e-04 | 9.13e-04 | 82 |
GO:005086315 | Oral cavity | OSCC | regulation of T cell activation | 161/7305 | 329/18723 | 1.44e-04 | 1.02e-03 | 161 |
GO:004311210 | Oral cavity | OSCC | receptor metabolic process | 88/7305 | 166/18723 | 1.68e-04 | 1.15e-03 | 88 |
GO:00469168 | Oral cavity | OSCC | cellular transition metal ion homeostasis | 64/7305 | 115/18723 | 2.13e-04 | 1.40e-03 | 64 |
GO:000715916 | Oral cavity | OSCC | leukocyte cell-cell adhesion | 178/7305 | 371/18723 | 2.44e-04 | 1.57e-03 | 178 |
GO:190303715 | Oral cavity | OSCC | regulation of leukocyte cell-cell adhesion | 162/7305 | 336/18723 | 3.39e-04 | 2.08e-03 | 162 |
GO:0006310 | Oral cavity | OSCC | DNA recombination | 147/7305 | 305/18723 | 6.33e-04 | 3.56e-03 | 147 |
GO:004209816 | Oral cavity | OSCC | T cell proliferation | 100/7305 | 199/18723 | 7.93e-04 | 4.27e-03 | 100 |
GO:002240917 | Oral cavity | OSCC | positive regulation of cell-cell adhesion | 136/7305 | 284/18723 | 1.35e-03 | 6.62e-03 | 136 |
GO:190303910 | Oral cavity | OSCC | positive regulation of leukocyte cell-cell adhesion | 115/7305 | 239/18723 | 2.48e-03 | 1.09e-02 | 115 |
GO:00550728 | Oral cavity | OSCC | iron ion homeostasis | 46/7305 | 85/18723 | 3.31e-03 | 1.42e-02 | 46 |
GO:00080531 | Oral cavity | OSCC | mitochondrial fusion | 18/7305 | 27/18723 | 3.34e-03 | 1.42e-02 | 18 |
GO:005087010 | Oral cavity | OSCC | positive regulation of T cell activation | 104/7305 | 216/18723 | 3.76e-03 | 1.55e-02 | 104 |
GO:00331354 | Oral cavity | OSCC | regulation of peptidyl-serine phosphorylation | 72/7305 | 144/18723 | 4.66e-03 | 1.87e-02 | 72 |
GO:0033138 | Oral cavity | OSCC | positive regulation of peptidyl-serine phosphorylation | 55/7305 | 108/18723 | 7.75e-03 | 2.84e-02 | 55 |
GO:00706618 | Oral cavity | OSCC | leukocyte proliferation | 145/7305 | 318/18723 | 9.31e-03 | 3.33e-02 | 145 |
GO:00487713 | Oral cavity | OSCC | tissue remodeling | 84/7305 | 175/18723 | 9.39e-03 | 3.36e-02 | 84 |
GO:0045453 | Oral cavity | OSCC | bone resorption | 35/7305 | 65/18723 | 1.07e-02 | 3.64e-02 | 35 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414520 | Cervix | CC | Phagosome | 47/1267 | 152/8465 | 3.95e-07 | 4.26e-06 | 2.52e-06 | 47 |
hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0421614 | Cervix | CC | Ferroptosis | 14/1267 | 41/8465 | 1.75e-03 | 7.21e-03 | 4.26e-03 | 14 |
hsa0406618 | Cervix | CC | HIF-1 signaling pathway | 27/1267 | 109/8465 | 4.72e-03 | 1.64e-02 | 9.72e-03 | 27 |
hsa04145110 | Cervix | CC | Phagosome | 47/1267 | 152/8465 | 3.95e-07 | 4.26e-06 | 2.52e-06 | 47 |
hsa0414419 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0421615 | Cervix | CC | Ferroptosis | 14/1267 | 41/8465 | 1.75e-03 | 7.21e-03 | 4.26e-03 | 14 |
hsa0406619 | Cervix | CC | HIF-1 signaling pathway | 27/1267 | 109/8465 | 4.72e-03 | 1.64e-02 | 9.72e-03 | 27 |
hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa04066 | Colorectum | AD | HIF-1 signaling pathway | 48/2092 | 109/8465 | 7.25e-06 | 7.84e-05 | 5.00e-05 | 48 |
hsa04216 | Colorectum | AD | Ferroptosis | 21/2092 | 41/8465 | 2.23e-04 | 1.78e-03 | 1.13e-03 | 21 |
hsa041441 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa040661 | Colorectum | AD | HIF-1 signaling pathway | 48/2092 | 109/8465 | 7.25e-06 | 7.84e-05 | 5.00e-05 | 48 |
hsa042161 | Colorectum | AD | Ferroptosis | 21/2092 | 41/8465 | 2.23e-04 | 1.78e-03 | 1.13e-03 | 21 |
hsa041444 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
hsa040664 | Colorectum | MSS | HIF-1 signaling pathway | 39/1875 | 109/8465 | 7.61e-04 | 5.00e-03 | 3.06e-03 | 39 |
hsa042162 | Colorectum | MSS | Ferroptosis | 18/1875 | 41/8465 | 1.53e-03 | 8.53e-03 | 5.23e-03 | 18 |
hsa041445 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
hsa040665 | Colorectum | MSS | HIF-1 signaling pathway | 39/1875 | 109/8465 | 7.61e-04 | 5.00e-03 | 3.06e-03 | 39 |
hsa042163 | Colorectum | MSS | Ferroptosis | 18/1875 | 41/8465 | 1.53e-03 | 8.53e-03 | 5.23e-03 | 18 |
Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TFRC | SNV | Missense_Mutation | rs769366579 | c.1511C>T | p.Thr504Met | p.T504M | P02786 | protein_coding | deleterious(0.05) | benign(0.055) | TCGA-AN-A0FZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TFRC | SNV | Missense_Mutation | novel | c.145N>T | p.Asp49Tyr | p.D49Y | P02786 | protein_coding | deleterious(0.01) | possibly_damaging(0.819) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
TFRC | insertion | Frame_Shift_Ins | novel | c.1815_1816insTTCCCCTATAGGGACATTTTCCCCCAAAAGGA | p.Glu606PhefsTer13 | p.E606Ffs*13 | P02786 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
TFRC | SNV | Missense_Mutation | rs41298067 | c.2030G>A | p.Arg677His | p.R677H | P02786 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TFRC | SNV | Missense_Mutation | novel | c.323T>C | p.Val108Ala | p.V108A | P02786 | protein_coding | tolerated(0.85) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TFRC | SNV | Missense_Mutation | novel | c.2249N>T | p.Ser750Phe | p.S750F | P02786 | protein_coding | deleterious(0.02) | possibly_damaging(0.882) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TFRC | SNV | Missense_Mutation | rs764730449 | c.2155N>T | p.Arg719Cys | p.R719C | P02786 | protein_coding | tolerated(0.14) | probably_damaging(0.981) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TFRC | SNV | Missense_Mutation | novel | c.349N>G | p.Leu117Val | p.L117V | protein_coding | deleterious_low_confidence(0.02) | unknown(0) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
TFRC | SNV | Missense_Mutation | rs370784605 | c.395C>T | p.Ser132Leu | p.S132L | P02786 | protein_coding | deleterious(0.02) | probably_damaging(0.976) | TCGA-VS-A9UL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
TFRC | SNV | Missense_Mutation | rs772641140 | c.362N>A | p.Arg121His | p.R121H | P02786 | protein_coding | tolerated(0.57) | benign(0) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |